Curing Versus Managing CLL
Adrian Wiestner, MD, PhD, senior investigator, National Institutes of Health, discusses curing or managing patients with chronic lymphocytic leukemia (CLL).
Clinical Pearls
Adrian Wiestner, MD, PhD, senior investigator, National Institutes of Health, discusses curing or managing patients with chronic lymphocytic leukemia (CLL).
- The question remains as to whether CLL can be cured or if it should be managed over the long term.
- This answer depends on the age and comorbidities of the patient.
- The safety of CLL drugs over the course of many years in unknown.
<<<
PTCy Offers New Hope for Mismatched Stem Cell Transplants in Leukemia, MDS
April 13th 2024Jeff Auletta, MD, discussed how PTCy-based graft-vs-host disease prophylaxis offers a promising approach for expanding access to successful cell transplantation regardless of donor match or patient ethnicity.
Read More
Considering the Durability of Zanubrutinib in Relapsed/Refractory CLL
April 11th 2024During a Case-Based Roundtable® event, Marc S. Hoffmann, MD, discussed his viewpoints on the use of Bruton tyrosine kinase inhibitors for patients with relapsed/refractory chronic lymphocytic leukemia and the efficacy behind zanubrutinib in the second article of a 2-part series.
Read More
